Trends in innovative drug development in China

Xian Su,Haixue Wang,Nan Zhao,Tao Wang,Yimin Cui

DOI: https://doi.org/10.1038/d41573-022-00077-3

IF: 112.288

2022-05-05

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 05 May 2022; doi:10.1038/d41573-022-00077-3 Trends in innovative drug development in China

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

Evolution of innovative drug R&D in China

Guanqiao Li,Yang Liu,Hongxi Hu,Shuona Yuan,Liyun Zhou,Xiaoyuan Chen

DOI: https://doi.org/10.1038/d41573-022-00058-6

IF: 112.288

2022-04-01

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 01 April 2022; doi:10.1038/d41573-022-00058-6Evolution of innovative drug R&D in China

pharmacology & pharmacy,biotechnology & applied microbiology
Development of Chinese innovative drugs in the USA

Qianwei Ge,Xuan Zhang,Kenneth I. Kaitin,Liming Shao

DOI: https://doi.org/10.1038/d41573-024-00079-3

IF: 112.288

2024-05-09

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 08 May 2024; doi:10.1038/d41573-024-00079-3 Development of Chinese innovative drugs in the USA

pharmacology & pharmacy,biotechnology & applied microbiology
Chinese innovative drug R&D trends in 2024.

Zimeng Chen,Hui Zhong,Hongxi Hu,Fanpu Kong,Wannian Liang,Guanqiao Li

DOI: https://doi.org/10.1038/d41573-024-00120-5

2024-01-01

Abstract:Discover the world’s best science and medicine | Nature.com
Challenges in Anticancer Drug R&D in China

Shen Zhao,Cheng Lv,Jifang Gong,Fang Wenfeng,Xichun Hu,Yi Ba,Chen Xiaoyuan,Yang Zhimin,Lin Shen,Li Zhang

DOI: https://doi.org/10.1016/s1470-2045(18)30865-9

IF: 54.433

2019-01-01

The Lancet Oncology

Abstract:The availability of innovative drugs in China has long been compromised by the so-called drug lag, in which a lengthy drug review processes, scarcity of domestically developed innovative drugs, overly strict policies in clinical trial application, and import drug registration has impeded drug innovation. 1 Shao L Xu L Li Q Chakravarthy R Yang Z Kaitin KI Regulatory watch: innovative drug availability in China. Nat Rev Drug Discov. 2016; 15: 739-740 Google Scholar , 2 Mullard A Chinese biopharma starts feeding the global pipeline. Nat Rev Drug Discov. 2017; 16: 443-446 Google Scholar To tackle this dilemma, the Chinese Government has issued a series of regulatory reforms on drug administration since 2017. 3 China Food and Drug AdministrationPolicies on reforming clinical trial administrations and encouraging drug and medical device innovations. http://samrcfdagovcn/WS01/CL0087/172568htmlDate: 2017 Date accessed: April 8, 2018 Google Scholar , 4 China Food and Drug AdministrationNotice of the general administration of the people's republic of China on releasing the work program for the reform of the classification of chemical drugs registration. http://samrcfdagovcn/WS01/CL0087/146603htmlDate: 2016 Date accessed: April 8, 2018 Google Scholar , 5 China Food and Drug AdministrationOpinions of the state council regarding deepening reforms on the examination and approval system, encouraging drug and medical device innovations. http://wwwgovcn/xinwen/2017-10/08/content_5230105htmDate: 2017 Date accessed: April 8, 2018 Google Scholar , 6 China Food and Drug AdministrationDecisions about adjustments of regulations on import drug registration and management. http://samrcfdagovcn/WS01/CL1031/178363htmlDate: 2017 Date accessed: April 3, 2018 Google Scholar , 7 China Food and Drug AdministrationPolicies on accelerating reviews and approvals of new drugs and medical devices to encourage drug and medical device innovations. http://samrcfdagovcn/WS01/CL0087/172567htmlDate: 2017 Date accessed: April 4, 2018 Google Scholar The changing landscape of drug research and development (R&D) in China is captured by an annual report of China's phase 1 oncology studies (appendix).
The Increasing Impact of Chinese Innovative Drug Research on the Global Stage with a Focus on Drug Discovery

Wei Luo,Cherukupalli Srinivasulu,Xia Hao,Xinyong Liu,Peng Zhan

DOI: https://doi.org/10.1080/17460441.2020.1775577

2020-01-01

Expert Opinion on Drug Discovery

Abstract:After China’s reform and opening up, notably since the implementation of ‘the national significant new drug innovation program,’ China’s biopharma has achieved rapid development, Chinese scientists...
Trends in innovative pediatric drug development in China based on clinical trial registration data

Wen-Wen Wu,Xing Ji,Xin-Shuang Mou,Xin-Yue Ma,Ya-Ting Huang,Jie-Ying Zhang,Jing-Xian Zhang,Xin-Rong Xie,Ning-Ying Mao,Jing Xu

DOI: https://doi.org/10.3389/fmed.2023.1187547

IF: 3.9

2023-07-06

Frontiers in Medicine

Abstract:In China, the focus of drug research and development has gradually shifted from generic to innovative drugs. Using the Chinese Clinical Trials Registry and Information Transparency Platform, we retrospectively analyzed clinical trials of innovative pediatric drugs conducted in mainland China over the last decade. The goal of this work was to better understand the characteristics of and historical changes in innovative pediatric drug research and development (R&D) in China and to provide effective data support for policy makers and other stakeholders. This study included 198 innovative pediatric drug clinical trials. The data showed that, although some progress has been made in the R&D of innovative pediatric drugs in China, many factors limiting this progress still exist, such as concentrated R&D areas, inadequate pediatric participants, and unbalanced source distributions. The level of innovative pediatric drug R&D in China currently lags behind the global level and has not kept pace with anti-neoplastic drug R&D in China. To promote the innovative development of pediatric drugs in China, the Chinese government must develop an R&D supervision framework, improve the motivation and innovation capabilities of pharmaceutical companies, and optimize the source distribution between regions.

medicine, general & internal
Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024

Yipeng Lan,Xiaofeng Lin,Yanmei Rao,Zhe Huang

DOI: https://doi.org/10.1016/j.drudis.2024.104240

IF: 8.369

2024-11-18

Drug Discovery Today

Abstract:China has initiated drug regulatory reforms since 2015. Here, we analyze the characteristics and trends of domestic innovative drugs approved for marketing in China from January 2010 to May 2024 to explore the effectiveness of drug regulatory reform. Overall, 219 drugs were approved, with growth in chemicals and therapeutic biologics post-reform. Single-arm trials as an important option for clinical trial design of antineoplastic agents increased. The time for each link from investigational new...

pharmacology & pharmacy
Trends in Oncology Drug Innovation in China

Li, Guanqiao,Qin, Yunhe,Xie, Cuicui,Wu, Yi-Long,Chen, Xiaoyuan

DOI: https://doi.org/10.1038/d41573-020-00195-w

2020-01-01

Abstract:Discover the world’s best science and medicine | Nature.com
Evolution of drug regulations and regulatory innovation for anticancer drugs in China

Yang Liu,Ning Zhang,Cuicui Xie,Yale Jiang,Yunhe Qin,Liyun Zhou,Yi Fan,Lianjie Ren,Chen Yin,Huan Yang,Wei Xie,Qing Zhai,Guanqiao Li,Hongzhuan Chen,Xiaoyuan Chen

DOI: https://doi.org/10.1016/j.apsb.2022.08.004

IF: 14.903

2022-08-14

Acta Pharmaceutica Sinica B

Abstract:Over the past two decades, China has introduced significant changes to drug regulations through regulatory innovations to accelerate drug review and approvals, keeping in line with the rapidly growing scientific innovation in drug research and development (R&D). In this study, we outlined the revolution of drug regulation in China since the establishment of the State Drug Administration in 1998. More particularly, we performed a comprehensive analysis of the newly approved anticancer drugs in China from the year 2005 to May 2021, as a powerful illustration of how the revolution has changed the drug R&D landscape. Innovative drug development in China has boomed, benefiting in particular from pro-innovation policies as well as expedited program designations by the authority. We found a significant increase in the number of both imported and domestic new anticancer drugs from 2005 to 2021, with the emergence of drugs with novel mechanisms of action, including immune checkpoint inhibitors and cell therapy products. Drug lag has also been dramatically shortened by more than 70% for imported drugs in years 2016–2020 compared to years 2006–2010. Furthermore, we provide an insight into the potential approaches to further optimize the science-based and clinical value-based regulatory and R&D drug ecosystem in China. This review provides evidence of the significant impacts of regulations and policies on drug R&D and suggests that the constantly adapting regulatory ecosystem will speed up drug development in China and worldwide.

pharmacology & pharmacy
Trends and Characteristics of New Drug Approvals in China, 2011–2021

Ling Su,Sen Liu,Guanqiao Li,Cuicui Xie,Huan Yang,Yang Liu,Chen Yin,Xiaoyuan Chen

DOI: https://doi.org/10.1007/s43441-022-00472-3

2022-01-01

Therapeutic Innovation & Regulatory Science

Abstract:Background In the past decade, the Chinese drug regulatory system has undergone many changes. A major reform starting in 2015 has significantly reshaped the regulatory processes. It was important to assess the impact of the reform on new drug approvals in China. Method We analyzed the temporal trends of regulatory characteristics of the new drugs approved by the Chinese regulatory agency from 2011 to 2021, using data collected in the Pharmcube database. Results A total of 353 new drugs were approved, including 220 small molecule drugs, 86 biological products and 47 vaccines. The annual number of new drug approvals increased dramatically since 2017, reaching a record high of 70 in 2021. The median NDA approval time was 15.4 months in 2017-2021, the shortest in the decade, and was significantly shorter than that in the pre-reform period. The newly instituted expedited pathways such as priority review (PR) and accelerated approval for urgently needed overseas drugs (UNOD) significantly reduced new drug application (NDA) approval times compared with standard review. For imported drugs, in 2017-2021, the median time difference between the first approval in the world and the approval in China was 5 years, representing significant “drug lag”. However, the proportion of the imported drugs approved in China within 3 years of its first foreign approval has increased to 24.4% in 2017-2021. Conclusion The regulatory reform has produced significant, positive immediate outcomes in several metrics of drug regulatory approval. China’s regulatory system will continue to evolve as there still are many areas requiring further reform and improvement.
Development of Drug Design in China:40 Years of Achievements

TAN XiaoQin,XIONG JiaCheng,ZHU TingFei,HUANG ZiMing,TONG XiaoChu,ZHENG MingYue,LUO XiaoMin,ZHANG Jian,YANG ShengYong,LI HongLin,TANG Yun,SHENG ChunQuan,ZHANG WanNian,CHEN KaiXian,LAI LuHua,JIANG HuaLiang

DOI: https://doi.org/10.1360/ssv-2019-0167

2019-01-01

Abstract:In China, research in drug design began in the late 1970s and has flourished in the early 2000s through several generations of effort, which has placed the research level of China in this field at the global forefront. With the application of computer-aided drug design approaches, many small-molecule drug candidates have entered the clinical trial stage, and some have been approved for therapeutic use by the National Drug Administration of China. This paper reviews the development of drug design in China and summarizes the main achievements in this field over the past 40 years in terms of establishment, growth, maturation, and thriving stages.
Critical insights into the evolving drug‐approval process in China

Mina Nikanjam,Razelle Kurzrock

DOI: https://doi.org/10.1002/cncr.35186

IF: 6.9209

2024-01-04

Cancer

Abstract:Efforts have been put forward to improve the therapeutic development process in China, and more novel therapies have been approved in recent years. It is important to develop and test novel therapies in China given differences in metabolism and tolerance compared with other populations.

oncology
Study on Sustainable China’s Pharmaceutical Innovation Ecosystem

Lina Chen,Tong Yu,Mengyuan Chen,Zhongqi Xu

DOI: https://doi.org/10.54691/bcpbm.v19i.650

2022-05-31

BCP Business & Management

Abstract:In recent years, China's pharmaceutical innovation has achieved remarkable results, with strong growth in innovative drug development driven by policy, talent, and investment. Through more than 20 years of development, China has initially established a relatively complete drug regulatory system of laws and regulations. At the same time, China's pharmaceutical innovation is also facing many challenges, including policy, talent, and investment. However, compared to the world's leading countries, there is still a gap in the quality of innovation in China's currently marketed pharmaceutical innovation ecosystem. By implementing the concept of scientific and risk-based assessment, this paper provides a comprehensive analysis of the current state of China's pharmaceutical innovation ecosystem and proposes future directions for development, including improving laws, regulations, policies, and technical guidelines promptly; improving the review decision-making mechanism and priority review mechanism to encourage the review of innovative drugs; optimising the organisational structure, approval process and resource allocation of regulatory bodies in a demand-driven manner to shorten the review time; and strengthening the clinical data.
Regulatory watch: Innovative drug availability in China.

Liming Shao,Lili Xu,Qiu Li,Ranjana Chakravarthy,Ziling Yang,Kenneth I Kaitin

DOI: https://doi.org/10.1038/nrd.2016.200

IF: 112.288

2016-01-01

Nature Reviews Drug Discovery

Abstract:Long regulatory review times and a large backlog of new drug applications at the China Food and Drug Administration (CFDA) are a source of considerable criticism from pharmaceutical companies and others concerned about delayed access to innovative medicines and disease treatments by patients in China. With the aim of addressing…
Recent Advances in Drug Development and Regulatory Science in China

Jie Chen,Naiqing Zhao

DOI: https://doi.org/10.1177/2168479018764661

2018-01-01

Therapeutic Innovation & Regulatory Science

Abstract:As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval processes, and to harmonize its regulatory science with international standards, the China Food and Drug Administration (CFDA) has initiated a series of major changes to its policies and regulations. This paper presents a snapshot of China’s pharmaceutical market, and research and development status, and introduces technical guidelines pertaining to clinical trials and new drug applications. The recent wave of ground-breaking reforms in CFDA’s regulatory science is discussed. Examples of clinical trials and new drug applications are provided throughout the discussion.
Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)

Chen Chen,Ning Lou,Xin Zheng,Shasha Wang,Haizhu Chen,Xiaohong Han

DOI: https://doi.org/10.3389/fmed.2021.777698

IF: 3.9

2021-12-17

Frontiers in Medicine

Abstract:Background: In recent years, the number of clinical trials initiated in China has increased rapidly. The aim of this study was to overview the changing landscape of phase I clinical trials in mainland China from 2011 to 2020. Methods: We analyzed phase I clinical trials registered on 3 websites including the Chinese Clinical Trial Registry, ClinicalTrials.gov , and the China National Medical Products Administration Center for Drug Evaluation platform. Findings: A total of 2,842 phase I clinical trials were posted from January 1, 2011, to December 31, 2020. The overall number of clinical trials for innovative drugs was 1,497, accounting for half of all the phase I clinical trials (53%). Among these 1,486 innovative drug clinical trials, 924 were newly tested drugs with an average annual growth rate of 59%. Biological drug research increased significantly from 22.6% during 2011–2015 to 33.3% during 2016–2020. These principal investigators (PIs) of these clinical trials were mainly from Beijing ( n = 871), followed by Shanghai ( n = 496) and Jiangsu ( n = 281). As for the therapeutic area of phase I clinical trials, cancer took up the most percentage of all the clinical trials (35%), followed by infectious disease (9%), nervous system disease (9%), etc. Most phase I clinical trials are conducted on healthy volunteers ( n = 1,642, 57.8%), some cancer drugs are conducted in patients with cancer ( n = 846, 29.8%), and only a few clinical trials were conducted in the elderly ( n = 7). Among these clinical trials of the newly tested innovative drugs, the first in human (FIH) clinical trials accounted for 82% (744), and the First in Chinese (FIC) clinical trials only took up 18% (167). Only a small number of drugs could be made the transition to phase II ( n = 207, 22%). In addition, despite the number of newly tested drugs during 2011–2015 ( n = 163) was much less than that in 2016–2020 ( n = 761), the percentage of drugs that could enter into phase II clinical trials in 2011–2015 (34%) was higher than that in 2016–2020 (20%). Conclusion: In the past 10 years, the development of phase I clinical trials has achieved great progress in mainland China due to the novel design and drug innovation policy. Nevertheless, future efforts are needed to make for improving the phase transition success rate of innovative drugs.

medicine, general & internal
Trends of Drug Licensing in China: from Bring-in to Go-Global

Yale Jiang,Guo Zhao,Linlin Jia,Cheng Li,Xin Wang,Jing Cai,Huiyao Huang,Shuhang Wang,Ning Li

DOI: https://doi.org/10.1016/j.phrs.2024.107488

IF: 10.334

2024-01-01

Pharmacological Research

Abstract:Global medicine R&D has shown a stabilized trend after fleeting prosperity lately. Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and further boosted in 2023. A holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals. In-licensing showed a decreasing trend, while out-licensing was the opposite. Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies. With supportive policies of Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs. Biotech innovators are emerging as a dominant force with core innovation capacity. China is embracing international collaboration by showing favorable markets and high-level innovative products.
An overview of innovative cancer drug clinical development in China

Junli Xue

DOI: https://doi.org/10.1093/annonc/mdz301

IF: 51.769

2019-10-01

Annals of Oncology

Abstract:China starts to play more and more important role in the global arena of cancer drug development. From investigator’s perspective, this talk provides an overview of China cancer drug development, and strategy for future success. There are gaps between China and other countries in investment and length of drug development. With regulation reforms, cases show the drug development speed has been significantly improved. Large oncology patient population and unmet medical need make China an attractive market for cancer drug development. However, there is a big potential to be unleashed in early phase studies including phase I cancer trials in China. This talk also shares experience of how to build such an early clinical trial platform, with a professional clinical trial team, efficient management model and advanced technologies. Based on current situation, we need to discuss how to accelerate anticancer new drug research and develop more efficient and economic drugs for both China and Asian cancer patients.

oncology
Characteristics of expedited programmes for cancer drug approval in China

Guanqiao Li,Yang Liu,Cuicui Xie,Qing Zhou,Xiaoyuan Chen

DOI: https://doi.org/10.1038/d41573-021-00080-0

IF: 112.288

2021-05-10

Nature Reviews Drug Discovery

Abstract:<p>Nature Reviews Drug Discovery, Published online: 10 May 2021; <a href="https://www.nature.com/articles/d41573-021-00080-0">doi:10.1038/d41573-021-00080-0</a></p>Characteristics of expedited programmes for cancer drug approval in China

pharmacology & pharmacy,biotechnology & applied microbiology
Changes in Early-Phase Clinical Trials in China During 2013–2022: A Review

Jianxiong Zhang,Peng Zhang,Haixue Wang,Ruihua Dong

DOI: https://doi.org/10.1007/s40268-024-00489-z

2024-09-14

Drugs in R&D

Abstract:Clinical trials on innovative drugs in China have witnessed a stage of rapid development in recent years. The introduction of a number of government policies has stimulated enthusiasm for research and development in the pharmaceutical industry. We analyzed the data of the early-phase clinical trials registered in the Chinese Center for Drug Evaluation (CDE) from September 6, 2013, to December 31, 2022. All related registration information disclosed on the CDE website, including posted time, drug classification, dosing formula, indications, trial design, and trial status, were summarized and analyzed. A total of 5336 early-phase clinical trials were identified. The quantity and growth rate of early-phase clinical trials have increased substantially each year. Chemical drugs accounted for the largest proportion of early-phase clinical trials, although it dropped from 85.7% in 2013 to 59.5% in 2022. Moreover, the number of oncology drugs has increased yearly, accounting for 49.2% of all early-phase clinical trials in 2022. We can conclude that during 2013–2022, the development of early-phase clinical trials has progressed due to government support and advanced development techniques. To enhance the efficiency and success rate of early-phase clinical trials in the future, it is necessary to acquire advanced technical support and improve standardized supervision systems.

pharmacology & pharmacy

Trends in innovative drug development in China

Evolution of innovative drug R&D in China

Development of Chinese innovative drugs in the USA

Chinese innovative drug R&D trends in 2024.

Challenges in Anticancer Drug R&D in China

The Increasing Impact of Chinese Innovative Drug Research on the Global Stage with a Focus on Drug Discovery

Trends in innovative pediatric drug development in China based on clinical trial registration data

Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024

Trends in Oncology Drug Innovation in China

Evolution of drug regulations and regulatory innovation for anticancer drugs in China

Trends and Characteristics of New Drug Approvals in China, 2011–2021

Development of Drug Design in China:40 Years of Achievements

Critical insights into the evolving drug‐approval process in China

Study on Sustainable China’s Pharmaceutical Innovation Ecosystem

Regulatory watch: Innovative drug availability in China.

Recent Advances in Drug Development and Regulatory Science in China

Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011–2020)

Trends of Drug Licensing in China: from Bring-in to Go-Global

An overview of innovative cancer drug clinical development in China

Characteristics of expedited programmes for cancer drug approval in China

Changes in Early-Phase Clinical Trials in China During 2013–2022: A Review